Company Filing History:
Years Active: 2022
Title: Mohammad Al Hreebat: Innovator in Oral Dosage Forms
Introduction
Mohammad Al Hreebat is a notable inventor based in Amman, Jordan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms for cancer treatment. His innovative work focuses on improving the bioavailability and stability of important medications.
Latest Patents
Al Hreebat holds a patent for "Oral dosage forms of ibrutinib." This patent describes stable and bioavailable oral dosage forms of ibrutinib, which include an acidifying agent. The formulations may also contain a binder, such as sodium alginate, along with a surfactant, lubricant, filler, and/or disintegrant. The methods outlined in his patent are aimed at treating cancers, especially blood cancers, and graft versus host disease by administering these specialized dosage forms to patients in need.
Career Highlights
Al Hreebat is currently associated with Hikma Pharmaceuticals USA Inc., where he continues to work on innovative pharmaceutical solutions. His expertise in drug formulation has positioned him as a valuable asset in the industry.
Collaborations
He collaborates with talented professionals in his field, including Mahmoud Ghannam and Shahin Fesharaki. Their combined efforts contribute to advancing pharmaceutical research and development.
Conclusion
Mohammad Al Hreebat's work in developing oral dosage forms for ibrutinib showcases his commitment to improving cancer treatment options. His innovative contributions are paving the way for more effective therapies in the pharmaceutical industry.